Comments to FDA: Quality Attribute Considerations for Chewable Tablets

Share page:

Comments | Aug 16, 2016

Docket Number:
FDA-2016-D-1490

Our member companies generally support the recommendations found in the guidance but have concerns about the scope of hardness measurements and maximum break strength value.

Related Posts

Press Releases and Statements

CHPA Welcomes Three Consumer Healthcare Industry Members

Press Releases and Statements

CHPA Statement: OTC Pain Relievers and COVID-19 Vaccines